Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis

  title={Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis},
  author={Alexander Tsertsvadze and Howard A. Fink and Fatemeh Yazdi and Roderick MacDonald and Anthony J. Bella and Mohammed Toseef. Ansari and Chantelle Marie Garritty and Karla Soares-Weiser and Raymond Daniel and Margaret Sampson and Steven Fox and David Moher and Timothy J Wilt},
  journal={Annals of Internal Medicine},
Erectile dysfunction (ED) is a common male sexual disorder and is defined as the persistent inability to achieve or maintain penile erection sufficient for satisfactory sexual performance (1). Advanced age, diabetes, vascular diseases, psychiatric disorders, and possibly hypogonadism are associated with increased prevalence of ED (14). According to data from the Massachusetts Male Aging Study (2), the prevalence of ED in men aged 40 to 70 years is about 50%. Unless contraindicated, oral… 

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

Preliminary data suggest that the use of vardenafil may also be beneficial in cases of ED associated with premature ejaculation, and the evaluation of testosterone plasma levels will help to predict the efficacy of any PDE5-i.

Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.

  • Mary Lee
  • Medicine
    Clinical therapeutics
  • 2011

Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Since its advent, the class of agents known as type-5 phosphodiesterase (PDE5) inhibitors has revolutionized the management of ED and become the first-line therapy for ED, as recommended by the American Urological Association (AUA) and the European Association of Urology (EAU).

Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease

This chapter aims to present a pragmatic approach for the clinical diagnosis and therapy of ED, based on available literature, particularly the guidelines of the European Association of Urology, the American Urological Association, as well as the British Society for Sexual Medicine, and on current research and clinical practice.

A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction

Mirodenafil appears to be effective, safe and well tolerated in men with both ED and hypertension or lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) who are taking concomitant antihypertensive medications or α1-blockers.

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

The current state of the art with respect to this new management strategy for ED is reviewed, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

A Comparative Analysis of Phosphodiesterase 5 Inhibitors and Testosterone in Men with Erectile Dysfunction and Low Testosterone

Combination therapy was clinically more effective than monotherapy for ED with low testosterone and there was no significance in mean difference in age, systolic blood pressure, testosterone level or BMI for treatment type.

Current Diagnosis and Management of Erectile Dysfunction

Treatment can be initiated using appropriate medical therapies, including phosphodiesterase type 5 (PDE5) inhibitors, and transurethral or intracavernosal therapies, with surgical intervention via revascularization or penile prosthesis placement in men demonstrating a lack of response to medical therapy.

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated, and published data seem to suggest that there are no major differences in their safety profiles.

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction

Differences in efficacy and side effects between various members of the oral selective phosphodiesterase-5 inhibitor class of drugs are addressed.



Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.

Mirodenafil, in doses of 50 or 100 mg, significantly improved erectile function and were well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.

Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Results show that sildenafil is a well tolerated and effective oral therapy for male erectile dysfunction with no established organic cause and may represent a new class of peripherally acting drug for the treatment of this condition.

Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men

Oral sildenafil is a well‐tolerated and potentially efficacious oral treatment for ED in men with diabetes mellitus and erectile dysfunction and was found to be safe and effective in both men and women.

The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.

Udenafil is an effective and well-tolerated therapy for ED of broad-spectrum etiology and severity in patients with ED of diverse origin and severity.

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.

Vardenafil statistically improved erectile function and was generally well tolerated in these diabetic patients with ED and was effective in increasing intercourse success rates at all levels of baseline ED severity, at each level of plasma HbA(1c), and for type 1 and 2 diabetes.

Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open‐label uncontrolled study

It is assumed that testosterone‐induced remodelling of penile tissue structure is one underlying reason for the observed improvement of erectile function and the results imply that this process may require a longer period of testosterone administration than 4 weeks.

Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.

Vardenafil significantly improves EF in hypertensive men treated with concomitant antihypertensive medication, is well tolerated, and does not significantly affect blood pressure.

Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology.

Sildenafil is an effective and well-tolerated treatment for ED of psychogenic or mixed aetiology with once-daily dosing and was associated with significant improvement in the partners' own sex lives.

Duration of action of sildenafil citrate in men with erectile dysfunction.

Sildenafil improved objective and self-assessed erectile function in men with ED, and the duration of action of sildanafil was longer than that previously reported.